Enavate Sciences GP, LLC
•CIK: 1953107•Filing: Q4 2025
**Enavate Sciences GP, LLC** manages $507M across a concentrated portfolio of seven positions. The fund exhibits a significant overweighting in biotechnology, with ZBIO representing the largest holding at $142.3M. Key allocations include IMNM ($102.4M) and SION ($101.9M), indicating a focused, high-conviction approach within the life sciences sector. This structure suggests a deep, research-driven mandate targeting disruptive therapeutic assets.
Total AUM
$506.8M
QoQ Performance
+54.7%
Positions
7
Top 10 Concentration
100.0%
Latest Filing
Q4 2025
Top Holdings Allocation
ZBIO
IMNM
SION
UPB
CMPX
BBOT
ZBIO28.1%
IMNM20.2%
SION20.1%
UPB13.2%
CMPX8.3%
BBOT6.5%
CAMP3.7%
📈 Biggest Buys
ZBIO
ZENAS BIOPHARMA INC
+4.2%
28.1% of portfolio
📉 Biggest Sells
CAMP
CAMP4 THERAPEUTICS CORP
-19.8%
3.7% of portfolio
Sector Breakdown
Other100.0%
Changes from Q3 2025
↑1 increased
↓1 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024